Patients aged 70 years or older had similar survival outcomes compared to their younger counterparts when undergoing nonmyeloablative, related haploidentical bone marrow or peripheral blood stem cell transplants for the treatment of hematologic malignancies, according to the results of a study presented at the 2013 ASH meeting.
Ponatinib showed significant antileukemic activity in patients with CML and ALL, according to a phase II study that included a wide range of disease stages and mutation status; patients in the trial had a relatively high rate of adverse thrombotic events, an issue which has led to recent regulatory controversy surrounding the drug.
In a front-line trial of older patients with newly diagnosed chronic lymphocytic leukemia, obinutuzumab topped rituximab, demonstrating improvements in response rate and progression-free survival, according to results presented at the ASH annual meeting.
Patients of non-white northern European descent have better access to transplant than ever before due to access to cord blood and haploidentical transplants, a new study presented at the ASH annual meeting indicated.
In two phase III trials, the mTOR inhibitor temsirolimus failed to improved progression-free survival outcomes for patients with metastatic renal cell carcinoma compared with other therapeutic options.
Women who developed a rash early in their treatment for HER2-positive breast cancer with lapatinib were more likely to go on to have pathologic complete response compared to those who did not get a rash, according to the results of an unplanned analysis of data from the NeoALTTO trial.
A new study shows that men who have a specific protein marker present in their prostate biopsy may benefit from close follow-up and additional biopsies as they may be at increased risk of developing cancer.